IRWD Key Statistics, Chart & Performance
The current stock price of IRWD is 4.89 USD. In the past month the price increased by 45.1%. In the past year, price increased by 108.97%.
IRWD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IRWD. When comparing the yearly performance of all stocks, IRWD is one of the better performing stocks in the market, outperforming 98.22% of all stocks.
IRWD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IRWD. IRWD scores excellent on profitability, but there are concerns on its financial health.
IRWD Financial Highlights
Over the last trailing twelve months IRWD reported a non-GAAP Earnings per Share(EPS) of 0.26. The EPS increased by 2700% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.42% | ||
| ROA | 7.21% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IRWD Forecast & Estimates
9 analysts have analysed IRWD and the average price target is 4.95 USD. This implies a price increase of 1.17% is expected in the next year compared to the current price of 4.89.
For the next year, analysts expect an EPS growth of 1353.5% and a revenue growth -15.64% for IRWD
IRWD Ownership
IRWD Latest News, Press Relases and Analysis
About IRWD
Company Profile
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Company Info
IRONWOOD PHARMACEUTICALS INC
100 Summer Street, Suite 2300
Boston MASSACHUSETTS 02110 US
CEO: Mark Mallon
Employees: 253
Phone: 16176217722
IRONWOOD PHARMACEUTICALS INC / IRWD FAQ
What does IRWD do?
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Can you provide the latest stock price for IRONWOOD PHARMACEUTICALS INC?
The current stock price of IRWD is 4.89 USD. The price increased by 0.62% in the last trading session.
What is the dividend status of IRONWOOD PHARMACEUTICALS INC?
IRWD does not pay a dividend.
How is the ChartMill rating for IRONWOOD PHARMACEUTICALS INC?
IRWD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for IRWD stock?
9 analysts have analysed IRWD and the average price target is 4.95 USD. This implies a price increase of 1.17% is expected in the next year compared to the current price of 4.89.
How is the valuation of IRONWOOD PHARMACEUTICALS INC (IRWD) based on its PE ratio?
The PE ratio for IRONWOOD PHARMACEUTICALS INC (IRWD) is 18.81. This is based on the reported non-GAAP earnings per share of 0.26 and the current share price of 4.89 USD.
Can you provide the short interest for IRWD stock?
The outstanding short interest for IRONWOOD PHARMACEUTICALS INC (IRWD) is 5.16% of its float.